ClinicalTrials.gg
CompletedNCT01224171GEMINI IIIUpdated Jul 21, 2014Results posted

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

A Phase 3 interventional study of vedolizumab and Placebo in Crohn's Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 41 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-21.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
5th of 39
416 · median 101
Started
2010
the only one that year
Phase 3
16 of 39
6 open now
Registered
5th of 39
by date
Lead sponsor
4 of 39
Millennium Pharmaceuticals, Inc.

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 16 in phase 3, and was the 5th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.

Read the detailed description

After completing the study, patients were eligible to enroll in a long term safety study with continued access to vedolizumab (study C13008; NCT00790933) if study drug was well tolerated, and no major surgical intervention for Crohn's disease occurred or was required.

Participants who did not enroll in Study C13008 were to complete the Final Safety visit (16 weeks after the last dose of study drug) for a maximum time on study of 22 weeks.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80
  • Diagnosis of moderately to severely active Crohn's disease
  • Crohn's Disease involvement of the ileum and/or colon
  • Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least one conventional therapy as defined by the protocol
  • May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol

Exclusion criteria

Exclusion Criteria

  • Evidence of abdominal abscess at the initial screening visit
  • Extensive colonic resection, subtotal or total colectomy
  • History of >3 small bowel resections or diagnosis of short bowel syndrome
  • Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  • Have received non permitted therapies within either 30 or 60 days, depending on the medication, as stated in the protocol
  • Chronic or C infection; (HIV) infection
  • Active or latent tuberculosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
416 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo intravenous infusion at Weeks 0, 2 and 6.

    Other: Placebo

  • Experimental
    Vedolizumab

    Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.

    Drug: vedolizumab

Interventions

  • Vedolizumab for intravenous infusion

    Also known as: Entyvio, MLN0002, MLN02, LDP-02

  • OtherPlacebo

    Placebo intravenous infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 6

Secondary outcomes

  1. Percentage of Participants in Clinical Remission at Week 6 in the Overall Population

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 6

  2. Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 10

  3. Percentage of Participants in Clinical Remission at Week 10 in the Overall Population

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 10

  4. Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population

    Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.

    Time frame: Week 6 and Week 10

  5. Percentage of Participants With Sustained Clinical Remission in the Overall Population

    Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.

    Time frame: Week 6 and Week 10

  6. Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation

    Enhanced clinical response is defined as a ≥ 100-point decrease in CDAI score from Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percent deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.

    Time frame: Baseline and Week 6

  7. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was any AE, occurring at any dose and regardless of causality that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event based upon appropriate medical judgment that may have jeopardized the patient and may have required medical or surgical intervention to prevent 1 of the outcomes listed above, or any diagnosis of progressive multifocal leukoencephalopathy (PML). Relationship to study drug administration was determined by the investigator responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug?

    Time frame: From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.

07

Results

Posted Jul 21, 2014

Participant flow

Participants with moderately to severely active Crohn's Disease took part in the study at 107 sites worldwide from 24 November 2010 to 12 April 2012. Approximately 75% of participants were to have previously failed tumor necrosis factor alpha (TNFα) antagonist therapy and approximately 25% were to have been naïve to TNFα antagonist therapy.

Participant flow — Overall Study
MilestonePlaceboVedolizumab
Started207209
Tnfα antagonist failure population157158
Completed192196
Not completed1513
Withdrew: Adverse event84
Withdrew: Protocol violation01
Withdrew: Lack of efficacy51
Withdrew: Withdrawal of consent24
Withdrew: Lost to follow-up03

Outcome measures

PrimaryPercentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation
percentage of participantsPlaceboVedolizumab
Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation12.1 (7.0 to 17.2)15.2 (9.6 to 20.8)
Statistical analysis
  • Placebo vs Vedolizumab · Cochran-Mantel-Haenszel · p = 0.4332 · Risk difference (rd): 3.0 · 95% CI -4.5 to 10.5Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
SecondaryPercentage of Participants in Clinical Remission at Week 6 in the Overall Population

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission at Week 6 in the Overall Population
percentage of participantsPlaceboVedolizumab
Percentage of Participants in Clinical Remission at Week 6 in the Overall Population12.1 (7.6 to 16.5)19.1 (13.8 to 24.5)
SecondaryPercentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation
percentage of participantsPlaceboVedolizumab
Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation12.1 (7.0 to 17.2)26.6 (19.7 to 33.5)
SecondaryPercentage of Participants in Clinical Remission at Week 10 in the Overall Population

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission at Week 10 in the Overall Population
percentage of participantsPlaceboVedolizumab
Percentage of Participants in Clinical Remission at Week 10 in the Overall Population13.0 (8.5 to 17.6)28.7 (22.6 to 34.8)
SecondaryPercentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population

Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.

Time frame:
Week 6 and Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population
percentage of participantsPlaceboVedolizumab
Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population8.3 (4.0 to 12.6)12.0 (7.0 to 17.1)
SecondaryPercentage of Participants With Sustained Clinical Remission in the Overall Population

Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.

Time frame:
Week 6 and Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Clinical Remission in the Overall Population
percentage of participantsPlaceboVedolizumab
Percentage of Participants With Sustained Clinical Remission in the Overall Population8.2 (4.5 to 12.0)15.3 (10.4 to 20.2)
SecondaryPercentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation

Enhanced clinical response is defined as a ≥ 100-point decrease in CDAI score from Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percent deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.

Time frame:
Baseline and Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation
percentage of participantsPlaceboVedolizumab
Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation22.3 (15.8 to 28.8)39.2 (31.6 to 46.9)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was any AE, occurring at any dose and regardless of causality that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event based upon appropriate medical judgment that may have jeopardized the patient and may have required medical or surgical intervention to prevent 1 of the outcomes listed above, or any diagnosis of progressive multifocal leukoencephalopathy (PML). Relationship to study drug administration was determined by the investigator responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug?

Time frame:
From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPlaceboVedolizumab
Any adverse event124117
Drug-related adverse event3434
Adverse event resulting in study discontinuation84
Serious adverse event1613
Serious infection adverse event02
Drug-related serious adverse event11
Serious adverse event resulting in discontinuation54
Death00

Adverse events

Collected over From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—16/207 (7.7%)29/207 (14%)
Vedolizumab—13/209 (6.2%)25/209 (12%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlaceboVedolizumab
Crohn's diseaseGastrointestinal disorders11/2072/209
Abdominal painGastrointestinal disorders1/2071/209
DehydrationMetabolism and nutrition disorders1/2070/209
PolyarthritisMusculoskeletal and connective tissue disorders1/2070/209
General physical health deteriorationGeneral disorders1/2070/209
DemyelinationNervous system disorders1/2070/209
UrticariaSkin and subcutaneous tissue disorders1/2070/209
PancreatitisGastrointestinal disorders0/2071/209
Small intestinal obstructionGastrointestinal disorders0/2071/209
Gastric ulcerGastrointestinal disorders0/2071/209
Most frequent other events
Most frequent other events
EventPlaceboVedolizumab
HeadacheNervous system disorders15/20711/209
PyrexiaGeneral disorders13/2077/209
NauseaGastrointestinal disorders5/20712/209

Baseline characteristics

The Overall Intent-to-treat (ITT) Population consisted of all randomized participants who received any amount of blinded study drug.

Age, Continuous
Age, Continuous(years)PlaceboVedolizumabTotal
Mean37.1 ± 13.1538.6 ± 12.1437.9 ± 12.66
Age, Customized
Age, Customized(participants)PlaceboVedolizumabTotal
< 35 years10588193
≥ 35 years102121223
Age, Customized
Age, Customized(participants)PlaceboVedolizumabTotal
< 65 years202206408
≥ 65 years538
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVedolizumabTotal
Female118118236
Male8991180
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboVedolizumabTotal
Hispanic or Latino448
Not Hispanic or Latino199204403
Unknown or Not Reported415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVedolizumabTotal
White186188374
Black549
Asian9918
Other7613
Not Reported022
Body Weight
Body Weight(kg)PlaceboVedolizumabTotal
Mean71.3 ± 19.2269.5 ± 17.7670.4 ± 18.50
Body Mass Index
Body Mass Index(kg/m^2)PlaceboVedolizumabTotal
Mean24.6 ± 6.1324.0 ± 5.1324.3 ± 5.65

15 further baseline measures are reported on the registry.

08

Study locations

41 sites
  • Gastroenterology of the Rockies
    Lafayette, Colorado 80026, United States
  • Gastroenterology Center of Connecticut P.C.
    Hamden, Connecticut 65180, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Atlanta Gastroenterology Specialist PC
    Suwanee, Georgia 30024, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Cotton O'Neil Digestive Health Center
    Topeka, Kansas 66606, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University Of Louisville
    Louisville, Kentucky 40402, United States
  • Gastroenterology Associates
    Baton Rouge, Louisiana 70809, United States
  • Gastroenterology Research of New Orleans
    Hammond, Louisiana 70403, United States
  • Metropolitan Gastroenterology Group P.C.
    Chevy Chase, Maryland 20815, United States
  • Mid-Atlantic Medical Research Center
    Hollywood, Maryland 20636, United States
  • Massachusetts General Hospital Crohn's and Colitis Center
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • Minnesota Gastroenterology P.A.
    Plymouth, Minnesota 55446, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroenterology and Hepatology P.L.L.C
    Charlotte, North Carolina 28207, United States
  • Consultants for Clinical Research Inc.
    Cincinnati, Ohio 45219, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • The Oregon Clinic-West Hills Gastroenterology
    Portland, Oregon 97225, United States
  • Consultants in Gastroenterology
    Columbia, South Carolina 29203, United States
  • Gastroenterology Center of the MidSouth PC
    Germantown, Tennessee 38138, United States
  • Gastroenterology Clinic of San Antonio
    San Antonio, Texas 78229, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • University of Washington School of Medicine
    Seattle, Washington 98195, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
  • Medical College Of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Zeidler Ledcor Center-Univerisity of Alberta
    Edmonton, Alberta T6G2X8, Canada
09

References and documents

Publications

  • Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384. PubMed 30615117 ↗
  • Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125. PubMed 30203005 ↗
  • Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29. Erratum In: Clin Gastroenterol Hepatol. 2020 Mar;18(3):759. doi: 10.1016/j.cgh.2020.01.013. PubMed 29857145 ↗
  • Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18. PubMed 26893500 ↗
  • Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20. Erratum In: Aliment Pharmacol Ther. 2015 Nov;42(9):1135. doi: 10.1111/apt.13365. PubMed 25996351 ↗
  • Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21. PubMed 24859203 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Feb 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 5 months after primary completion. A results delay was requested in Mar 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2010
First posted
Oct 19, 2010
Start
Nov 2010
Primary completionActual
Feb 2012
CompletionActual
Apr 2012
Results delay requested
Mar 7, 2013
Results first posted
Jul 21, 2014
Last update
Jul 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01224171
Responsible party
Sponsor
First posted
Oct 19, 2010
Start date
Nov 2010
Primary completion
Feb 2012
Completion
Apr 2012
Results posted
Jul 21, 2014
Last update
Jul 21, 2014

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion